|
|
səhifə | 4/6 | tarix | 07.01.2024 | ölçüsü | 15,76 Kb. | | #202382 |
| covid-19
- Week 1: Fever (77-98%) (intermittent or persistent), Fatigue/Malaise (11-52%), Dry cough (46-82%), dyspnea (3-31%);
- Less common: Sputum (33%), Myalgia (15%), Headache (13%), Sore throat (14%), Diarrhea (4%), Nausea/Vomiting (5%), Nasal congestion (4%), Hemoptysis (1%)
- Week 2 (~ day 6-9 of symptoms): ~ 15-20% develop severe dyspnea due to viral pneumonia
- Hospitalization, supportive care, oxygen
- Week 2-3: Of hospitalized patients, 1/3 ultimately need ICU care, with up to half needing intubation (i.e. ~5% of total diagnosed cases need ICU)
- Can rapidly decline (over 12-24 hrs) from mild hypoxia to frank ARDS
- Cytokine Storm, Multi-organ failure
- Late stage sudden cardiomyopathy/viral myocarditis, cardiac shock
- Age
- HTN
- Diabetes
- Coronary Heart Disease
- Hep B
- Cerebrovascular Disease
- COPD
- Cancer
- Children and pregnant women seem to do okay
https://avatorl.org/covid-19/?page=ClinicalData1099
Diagnosis - Travel History, Exposure and Symptoms most important
- Person Under Investigation Criteria
- No specific physical exam findings. Lungs may have rales or rhonchi.
- Hypoxia, even silent hypoxia, may be present, esp elders.
- Tachycardia and tachypnea.
- May present as severe asthma or COPD exacerbation.
Ancillary Studies - Most Common:
- WBC usually normal, Lymphopenia in 80%, Mild thrombocytopenia
- Low Procal; Bacterial coinfection rare
- CRP and D-Dimer elevated proportionate to severity (marker of poor prognosis); DIC over time
- Increased ALT/AST to 70-100 range; Occasional increased alk phos
- Mild elevation of creatinine
- Generally normal troponin
- CXR (sensitivity 59%):
- CT scan (sensitivity 86%; much better than RT-PCR!)
- Bilateral diffuse ground glass opacities, multifocal patchy consolidation, interstitial changes
- Changes prior to severe symptom onset!
- ECHO:
- Normal EF prior to late-onset sudden cardiogenic shock with dropping to EF <10%
- Co-infection rare but possible (5%)
Dostları ilə paylaş: |
|
|